Needham raised the firm’s price target on Alnylam (ALNY) to $377 from $320 and keeps a Buy rating on the shares after hosting an investor tour with its management team. The company has reiterated its 2025 total product revenue of $2.05B-2.25B, and the firm has come away incrementally more positive on the name and more bullish on the Amvuttra launch in ATTR-CM, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Promising Outlook: Analyst Joseph Stringer Raises Price Target Amid Optimism for Amvuttra Launch
- Alnylam’s NeuroFeeL Study: A New Frontier in Biomarker Research
- Alnylam price target raised to $360 from $300 at BMO Capital
- Alnylam Pharma Appoints New Chief R&D Officer
- Alnylam names Pushkal Garg as EVP, chief research and development officer